
Shares in a struggling oncology company have skyrocketed after a late-stage cancer patient taking one of its drugs saw her tumours apparently disappear.
Nasdaq-listed stock of Sydney-based Kazia Therapeutics surged 51.7 per cent to a five-month high of $US8.74 ($A13.43) in after-hours trading on Tuesday after the announcement.